Efficacy of Danlou Tablet in Patients with Non-ST Elevation Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention: Results from a Multicentre, Placebo-Controlled, Randomized Trial. (8th November 2016)

• Record Type: Journal Article
• Authors: Wang, Lei; Zhao, Xujie; Mao, Shuai; Liu, Shaonan; Guo, Xinfeng; Guo, Liheng; Du, Tinghai; Yang, Haiyu; Zhao, Fuhai; Wu, Keng; Cong, Hongliang; Wu, Yang; Yang, Phillip C.; Chen, Keji; Zhang, Minzhou
• Other Names: Son Chang-Gue Academic Editor.
• Is Part Of: Evidence-based complementary and alternative medicine. Volume 2016(2016)
• Publication Date: 2016-11-08
• Subjects: Alternative medicine -- Periodicals; 615.505
• DOI: 10.1155/2016/7960503
• Languages: English
• ISSNs: 1741-427X

Abstract

Abstract : This study seeks to investigate potential cardioprotection of Danlou Tablets in patients undergoing PCI with non-ST elevation acute coronary syndrome (NSTE-ACS). 219 patients with NSTE-ACS were randomised to Danlou Tablet pretreatment (n = 109 ) or placebo (n = 110 ). No patients received statins prior to PCI and all patients were given atorvastatin (10 mg/day) after procedure. The main endpoint was the composite incidence of major adverse cardiac events (MACEs) within 30 days after PCI. The proportion of patients with elevated levels of cTn I>5 × 99% of upper reference limit was significantly lower in the Danlou Tablet group at 8 h (22.0% versus 34.5%, p = 0.04 ) and 24 h (23.9% versus 38.2%, p = 0.02 ) after PCI. The 30-day MACEs occurred in 22.0% of the Danlou Tablet group and 33.6% in the placebo group (p = 0.06 ). The incidence of MACE at 90-day follow-up was significantly decreased in the Danlou Tablet group compared to the placebo group (23.9% versus 37.3%, p = 0.03 ). The difference between the groups at 90 days was the incidence of nonfatal myocardial infarction (22% versus 34.5%, p = 0.04 ). These findings might support that treatment with Danlou Tablet could reduce the incidence of periprocedural myocardial infarction in patients with ACS undergoing PCI.